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In Brief
Sujobert et al. show that specific AMPK
activation by GSK621 induces
cytotoxicity in AML but not in normal
hematopoietic cells. AMPK-mediated
cytotoxicity indeed requires mTORC1
activation that is unique to AML cells and
involves the eIF2a/ATF4 signaling
pathway. This indicates a potential for
AMPK-activating agents in the treatment
of mTORC1-overactivated cancers.
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AMPK is a master regulator of cellular metabolism
that exerts either oncogenic or tumor suppressor
activity depending on context. Here, we report that
the specific AMPK agonist GSK621 selectively kills
acutemyeloid leukemia (AML) cells but spares normal
hematopoietic progenitors. This differential sensitivity
results from a unique synthetic lethal interaction in-
volving concurrent activation of AMPK and mTORC1.
Strikingly, the lethality of GSK621 in primaryAMLcells
andAMLcell lines is abrogatedbychemical or genetic
ablation of mTORC1 signaling. The same synthetic
lethalitybetweenAMPKandmTORC1activation is es-
tablished inCD34-positive hematopoietic progenitors
by constitutive activation of AKT or enhanced in AML
cells by deletion of TSC2. Finally, cytotoxicity in AML
cells from GSK621 involves the eIF2a/ATF4 signaling
pathway that specifically results from mTORC1 acti-
vation. AMPK activation may represent a therapeutic
opportunity in mTORC1-overactivated cancers.INTRODUCTION
Conventional chemotherapy for acute myeloid leukemia (AML) is
curative in only a minority of patients, and toxicity limits its use in
the elderly and in those with comorbidities (Bu¨chner et al., 2012).
Therefore, novel strategies that specifically target AML cells
while sparing normal tissues are desperately needed. AMP-Acti-1446 Cell Reports 11, 1446–1457, June 9, 2015 ª2015 The Authorsvated Protein Kinase (AMPK) is a heterotrimeric serine/threonine
kinase that acts as a sensor of cellular energy and modulates
multiple cellular metabolic pathways (Hardie et al., 2012). In
particular, activation of AMPK inhibits mammalian Target of
Rapamycin Complex 1 (mTORC1)-dependent protein synthesis
(Inoki et al., 2003), and also fatty acid biosynthesis via inactivat-
ing phosphorylation of acetyl-Coa carboxylase (ACC) (Fullerton
et al., 2013). At the same time, AMPK also promotes catabolism,
including glucose uptake and subsequent glycolysis, fatty acid
oxidation, and autophagy (Hardie et al., 2012).
AMPK appears to act as either a tumor suppressor or an onco-
gene, depending on the context (Faubert et al., 2013; Jeon et al.,
2012; Shackelford et al., 2009, 2013). The indirect AMPK acti-
vator metformin has activity in cell line models of AML (Green
et al., 2010). However, the biological effects of biguanides
such as metformin and phenformine in cancer primarily involve
the general consequences of mitochondrial respiratory chain in-
hibition and are incompletely related to AMPK (Scotland et al.,
2013; Shackelford et al., 2013).
In the present study, we tested the AMPK activator GSK621 in
AML cells. We demonstrate that GSK621 is a direct and specific
activator of AMPK that induces cytotoxicity by activating auto-
phagy independent of mTORC1 inhibition. Unexpectedly, we
demonstrate that activation of AMPK and constitutive mTORC1
signaling results in a synthetic lethal interaction across a range of
AML primary samples and cell lines. The lack of constitutive
mTORC1 activation in normal hematopoietic progenitors there-
fore suggests a therapeutic window for AMPK activation in the
treatment of AML. Finally, we demonstrate that activation of
the eIF2a/ATF4 signaling pathway is critical for the synthetic le-
thal interaction between activated mTORC1 and AMPK. Taken
Figure 1. GSK621 Is a Specific and Potent
AMPK Activator
(A) Chemical structure of GSK621.
(B) ACC (S79) phosphorylation, reflecting AMPK
activation following increasing doses of GSK621
or A-769662 treatment, was assessed by ELISA in
the human HEPG2 cell line. Results are presented
for each condition as a percentage of vehicle-
treated cells (n = 5).
(C) AML cell lines and primary AML cells from
patient 2 were incubated 6 hr with vehicle or 30 mM
GSK621, and protein extracts were immuno-
blotted for the indicated markers.
(D) Annexin 5 binding (bottom) and western blot-
ting using AMPKa1 antibody (top) in MOLM-14
cells subjected to shRNA-induced AMPKa1
knockdown and cultured for 48 hr with vehicle or
30 mM GSK621 (n = 5).
(E) Trypan blue exclusion assay in single-cell
cloned MOLM-14 cells transduced with a control
(CTR) or a PRKAA1 CRISPR and treated for 48 hr
with vehicle or 30 mM GSK621. Right: western
blotting in these cell lines using anti-AMPKa1 and
anti-phospho-ACC (S79) antibodies. b-actin was
used as a loading control in western blot experi-
ments. Results in the graphs are expressed as the
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.together, these data provide insights into the role of mTORC1 in
AML and support the testing of therapeutic AMPK activators as a
therapeutic strategy in cancers with mTORC1 activation.
RESULTS
AMPK Activation by GSK621
To directly and potently target AMPK, we developed a thienopyr-
idone-derived compound GSK621 (Mirguet and Bouillot, 2011)
(Figure 1A) that consistently activated AMPK recombinant heter-
otrimers in vitro, however, less potently that the tool compound
A-769662 (Figure S1A). In cellular assays, GSK621 was at the
opposite more potent than A-769662 at inducing AMPK activa-
tion, as measured by the level of ACC phosphorylation (Fig-
ure 1B). We hypothesize that differences in intracellular uptake
may account for these results, as in MOLM-14 cells 200 mM A-
769662 is barely as potent as 30 mM GSK621 at inducing ACC
(S79) and ULK1 (S555) phosphorylation, two well-characterizedCell Reports 11, 1446–14direct AMPK substrates (Egan et al.,
2011) (Figure S1B). In AML cell lines
(MOLM-14, HL-60, and OCI-AML3) and
primary AML samples, GSK621 markedly
increased phosphorylation at AMPKa
T172, a marker of AMPK activation, and
also stimulated the phosphorylation of
ACC (S79) and ULK1 (S555) (Figure 1C).
These results suggest that GSK621 is a
potent AMPK activator in AML cells.
To clarify whether these effects are
dependent on AMPK in AML cells, we
depleted MOLM-14 cells of AMPKa1,which is the only AMPK catalytic subunit isoform expressed
in hematopoietic cells (Figures S1D and S1E). To that end,
we first used lentivirally expressed anti-AMPKa1 small hairpin
RNA (shRNA) in MOLM-14 cells. Following efficient AMPKa1
knockdown (Figure 1D), we incubated MOLM-14 cells with
vehicle or GSK621. AMPKa1-depleted cells had reduced an-
nexin V positivity after treatment with GSK621 (43.9% versus
73% for scrambled shRNA, p < 0.01; Figure 1D). To confirm
these results, we deleted the PRKAA1 gene that encodes
AMPKa1 by CRISPR/Cas9 genome editing. MOLM-14 cells
with homozygous PRKAA1 deletion lose AMPK function (Fig-
ures 1E, right, and S1E) and were significantly protected from
GSK621-induced cytotoxicity in contrast to cells expressing
control CRISPR (Figure 1E, left). Moreover, prolonged expo-
sure to GSK621 of a bulk lentivirally transduced population
led to the gradual selection of MOLM-14 cells lacking AMPKa1
expression (Figure S1F), suggesting that AMPKa1 depletion
protected AML cells from GSK621 cytotoxicity. We conclude57, June 9, 2015 ª2015 The Authors 1447
Table 1. Clinical and Molecular Characteristics of AML Patients
No. Age (yr) FAB Cytogenetic Molecular GSK621 R
AML#1 69 AML5 46, XX, t(11;22) EVI1over X X
AML#2 65 AML5 46, XY FLT3-ITD, NPM1mut, DNMT3Amut X
AML#3 78 AML5 46, XY — X X
AML#4 75 AML1 46, XX — X
AML#5 40 AML4 46, XX FLT3-ITD, NPM1mut X
AML#6 81 AML1 46, XX FLT3-ITD, NPM1mut, DNMT3Amut X
AML#7 48 AML4 46, XY, del(9) — X
AML#8 52 AML5 45, XX, 13, der(19)t(13;19) — X
AML#9 68 AML1 46, XX FLT3-ITD, NPM1mut X
AML#10 77 AML1 46, XY IDH2mut, ASXL1mut X
AML#11 61 AML5 46, XY SRSF2mut X
AML#12 76 AML1 46, XX N/A X X
AML#13 74 sAML 46, XX, 5q- — X X
AML#14 76 AML1 46 XX IDH2mut X X
AML#15 67 AML2 46 XX FLT3-ITD X X
AML#16 68 sAML 46 XX FLT3-ITD, NPM1mut X X
FAB, French American British Classification of AML; sAML, secondary AML; EVI1over, overexpression of ecotropic virus integration site 1; FLT3-
ITD, FLT3 Internal Tandem Duplication; NPM1mut, Nucleophosmin 1 mutation; DNMT3Amut, DNA (cytosine-5-)-methyltransferase 3 alpha mutation;
IDH2mut, Isocitrate Dehydrogenase 2 mutation; ASXL1mut, additional sex combs like 1 mutation; SRSF2mut, Serine/arginine-rich Splicing Factor 2
mutation; —, no molecular abnormality detected; N/A, information not available; R, rapamycin; X, sample involved in experiments done using
GSK621 or rapamycin as indicated.from these results that GSK621 is a specific AMPK agonist in
AML cells.
GSK621 Selectively Kills AML Cells In Vitro and In Vivo
To determine the activity of GSK621 in AML, we assayed a set
of 20 cell lines that captures the diversity of molecular abnormal-
ities across this disease (Table S1). IC50 of GSK621 for each cell
line ranged from 13 to 30 mM (Figures S2A and S2B). GSK621
(30 mM) reduced the proliferation of all 20 lines and increased
apoptosis in 17 (85%) lines (Figure 2A; Figures S2C and S2D).
We also exposed 16 primary AML samples corresponding
to different AML subtypes (Table 1) to 30 mM GSK621 and
consistently observed a significant induction of annexin V stain-
ing (p < 0.01 compared to vehicle treatment, Figure 2B). In
contrast, the same concentration of GSK621 had no effect on
annexin V positivity in normal human CD34+ hematopoietic pro-
genitor cells (n = 9, p = 0.84, Figure 2B).
To assess the impact of GSK621 on leukemic progenitor cells,
we generated murine AMLs by transduction of bone marrow he-
matopoietic cells with either MLL-ENL (Barabe´ et al., 2007) or
FLT3-ITD (Mizuki et al., 2000). After treatment with vehicle or
30 mMGSK621, AML cells were tested for serial replating capac-
ity (Figure 2C), which is a well-established indicator of stemness
in vitro (Yeung et al., 2010). GSK621 significantly reduced colony
formation after each replating for both MLL-ENL and FLT3-ITD
AMLs (Figure 2D), suggesting that GSK621 treatment depletes
not only the bulk, but also the AML progenitor population in vitro.
Next, we determined GSK621 in vivo activity by xenografting
MOLM-14 cells and treating with intraperitoneal injections of
vehicle or GSK621. GSK621 (30 mg/kg twice daily) reduced
leukemia growth (Figure 2E) and significantly extended survival1448 Cell Reports 11, 1446–1457, June 9, 2015 ª2015 The Authorscompared to vehicle-treated animals or those treated with
10 mg/kg twice daily GSK621 (Figure 2F). These results corre-
lated to enhanced AMPK activity (assessed by increased ACC
S79 phosphorylation) and the induction of apoptosis (by TUNEL
staining) (Figures 2G and S2E). As expected, GSK621 serum
concentrations 5 hr after dosing were significantly higher in
mice receiving 30 mg/kg compared to 10 mg/kg (Figure 2H). In
GSK621-treatedmice, no apparent toxicity was observed on he-
matopoiesis (Figure S2F), supporting the notion of a differential
sensitivity to GSK621 between normal and leukemic cells.
AMPK Activation Induces Autophagy and Cell Death
in AML
Although GSK621 clearly induced apoptosis across AML sub-
types, we hypothesized that AMPK activation would also induce
autophagy. As previously suggested, AMPK activation may
promote autophagy to restore energy balance (Egan et al.,
2011; Kim et al., 2011). Using transmission electronic micro-
scopy, we observed that GSK621 induced the formation of
numerous intracytoplasmic vacuoles including autophago-
somes, as defined by double membrane vesicles with cyto-
plasmic material (Figure 3A).
mTORC1 is a well-documented inhibitor of autophagy (Lamb
et al., 2013), but the effects of mTORC1 inhibition on autophagy
depend on both cell type (Budovskaya et al., 2004; Mizushima
et al., 2010; Takeuchi et al., 2005) and cellular context (Sheen
et al., 2011). In MOLM-14 cells, rapamycin had no impact on au-
tophagosome formation (Figure 3A). Similarly, rapamycin did not
promote LC3B-II accumulation by western blotting in AML cell
lines and primary AML samples, in contrast with GSK621 (Fig-
ure 3B). We confirmed autophagy induction in GSK621-treated
Figure 2. GSK621 Induces Anti-leukemic Activity in AML
(A) Apoptosis was determined in AML cell lines (MOLM-14, HL-60, OCI-AML3) incubated with vehicle or 30 mMGSK621 for up to 4 days by positivity for Annexin V
and negativity for 7-AAD staining by flow cytometry.
(B) Primary normal hematopoietic CD34+ progenitor cells (referred to as CD34+) and cells fromAML patients (AML) (CD34+, n = 9; AML, n = 16) were cultured 48 hr
with vehicle or 30 mM GSK621. Apoptosis was assessed by annexin V binding by flow cytometry.
(legend continued on next page)
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cells by flow cytometry for monodansylcadaverin (MDC) (Va´z-
quez and Colombo, 2009) (Figures 3C and 3D), and by immuno-
fluorescence analysis of LC3B protein, which showed a shift
from a diffuse intracellular localization to a dot-shaped distribu-
tion after GSK621 exposure (Figure 3E).
In MOLM-14 cells, chloroquine blocked the degradation of au-
tophagosomes, as attested by increased LC3B-II accumulation
(Figure 3F, top) (Mizushima et al., 2010). In the same chloro-
quine-treated AML cells, addition of GSK621 further induced
LC3B-II expression, consistent with autophagy induction. In
GSK621-treated MOLM-14 cells, chloroquine reduced annexin
V staining, suggesting that autophagy inhibition protected AML
cells from GSK621-induced cytotoxicity (Figure 3F, bottom).
Autophagy related (ATG) 5 and 7 play a critical role in the forma-
tion of autophagosomes (Lamb et al., 2013). ATG7 knockdown
reduced GSK621-induced autophagy, as assessed by western
blotting inMOLM-14 cells (Figure 3G, top), andGSK621-induced
apoptosis was reduced after knockdown of ATG7 (Figure 3G,
bottom) or ATG5 (Figure S3). Knockdown of ATG7 rescued the
loss of clonogenic growth capacity induced by GSK621 (Fig-
ure 3H). Together these results suggest that GSK621 treatment
triggers autophagy, which partially contributes to AML cell
death.
AMPK and mTORC1 Activation Are Synthetically Lethal
in AML
We hypothesized two different models (Figure 4A) for the role of
mTORC1 activity in the context of AMPK activation that may ac-
count for the preferential cytotoxicity of GSK621 in AML versus
normal hematopoietic cells. In the first model (oncogene addic-
tion), GSK621-induced AMPK activation suppresses mTORC1
activity, as we observed in HEK293 cells (Figure S4A) and previ-
ously shown after treatment of mouse embryonic fibroblasts
(MEFs) with 5-aminoimidazole-4-carboxamide-1-b-D-ribofura-
noside (AICAR) (Gwinn et al., 2008). In this model, inhibition of
mTORC1 directly contributes to AML cell death. Arguing against
this hypothesis, GSK621 did not inhibit mTORC1 in AML cell
lines (MOLM-14, HL-60, and OCI-AML3) and primary AML sam-
ples (Figure 4B), based on persistent phosphorylation of the
mTORC1 target p70S6K (T389). This indicates dissociation be-
tween AMPK activation and mTORC1 suppression in AML.
Similar results were reported in glioma, suggesting that the clas-
sical axis connecting AMPK with mTORC1 axis is cell type
dependent (Liu et al., 2014).
In the second model (synthetic lethality), sustained mTORC1
activity is required for the cytotoxic response to AMPK activa-
tion. To test this possibility, we first ectopically expressed a(C) Schematic representation of the mouse leukemia cell methylcellulose exper
cellulosis plating; P3, third methylcellulosis plating.
(D) Cells were plated at 5 3 104/ml in methylcellulose and incubated with vehic
methylcellulose culture, cells were washed in PBS seeded again in methylcellulos
successive replatings were performed.
(E and F) Tumor growth and survival (Kaplan-Meier curve) in MOLM-14 cells xeno
twice-daily intraperitoneal injections.
(G) Tumor sections were stained by TUNEL and DAPI or labeled with an anti-ph
shown.
(H) Plasma concentrations of GSK621 in mice treated with 10 or 30 mg/kg GSK6
expressed as the mean ± SEM. *p < 0.05, **p < 0.01.
1450 Cell Reports 11, 1446–1457, June 9, 2015 ª2015 The Authorsconstitutively active AKT allele (myrAKT) (Kharas et al., 2010)
in normal human CD34-positive (CD34+) hematopoietic progen-
itors. myrAKT activated mTORC1 in these cells, as evidenced by
phosphorylation of P70S6K (T389) and 4E-BP1 (S65) (Figure 4C,
right). GSK621 induced apoptosis only in myrAKT-transduced
CD34+ cells and not in control cells (Figure 4C, left). Strikingly,
this effect was reversed by co-treatment with rapamycin, indi-
cating that mTORC1 activity is required for GSK621-induced
cytotoxicity (Figure 4C, left). We overactivated mTORC1 in the
MOLM-14 cell line by deleting the negative regulator TSC2 (Inoki
et al., 2002, 2003) by CRISPR/Cas9 genome editing (Figure 4D).
Deletion of TSC2 resulted in mTORC1 overactivation (based on
increased p70S6K (T389) phosphorylation) and enhanced the
cytotoxicity of GSK621 (Figure 4D).
Strikingly, inhibition of mTORC1 by shRNA knockdown of
raptor or mTOR (Figures 4E and S4B) or by rapamycin (Figures
4F and S4C) protected AML cell lines from GSK621-induced
apoptosis. We confirmed these results in primary AML samples
in which rapamycin protected AML cells from apoptosis induced
by GSK621 (Figure 4G). We also used two other direct AMPK ac-
tivators, A769662 (Cool et al., 2006) and compound 991 (Xiao
et al., 2013). In AML cell lines, 991 induced apoptosis and co-in-
cubation with rapamycin significantly protected from 991 (Fig-
ure 4H). Cytotoxicity induced by A769662 was variable across
AML cell lines, as reported (Green et al., 2010), with significant
effects observed only in MOLM-14 cells (Figure 4H; data not
shown in HL-60 and OCI-AML2). Co-treatment with rapamycin
also protected MOLM-14 cells from A769662-induced cytotox-
icity (Figure 4H). While GSK621 induced cytoplasmic vacuoles,
pyknotic nuclei, and changes in cellular morphology in primary
AML cells, co-treatment with rapamycin blocked these effects
(Figure 4I). We conclude from these data that mTORC1 activity
is critical for the cytotoxic effects observed upon treatment
with AMPK activators including GSK621 in AML.
Synthetic Lethality between AMPK and mTORC1
Involves eIF2a/ATF4
To investigate the molecular basis of the synthetic lethal interac-
tion between mTORC1 and AMPK, we generated an unbiased
gene expression analysis in MOLM-14 cells treated with
GSK621 or co-treated with GSK621 and rapamycin. Among
the top ten Ingenuity canonical pathways scored by this analysis
(Figure S5A), the unfolded protein response (UPR) was the most
significantly inhibited by the addition of rapamycin in GSK621-
treated MOLM-14 cells (Figure 5A, –log(p value) = 6.28). In
fact, GSK621 induced eiF2a phosphorylation—a hallmark of
UPR activation—as well as upregulation of terminal effectors ofiments. BMC, mouse bone marrow cells; GSK, GSK621; P2, second methyl-
le or 30 mM GSK621. Colony formation was assessed at day 7. At the end of
e with or without GSK621 (this step is referred to as first replating). Up to three
grafted into nude mice treated with vehicle, 10 mg/kg, or 30 mg/kg GSK621 by
ospho-ACC (S79) antibody. Representative images of three experiments are
21 5 hr after intraperitoneal injection (n = 3 for each). Results in the graphs are
Figure 3. Autophagy Is a Trigger of GSK621-Induced AML Cell Death
(A) Electron microscopy-captured images of MOLM-14 cells treated 24 hr with vehicle, 10 nM rapamycin, or 30 mM GSK621 (12,0003magnification). Details of
GSK621-treated MOLM-14 cells (24,0003 magnifications) are provided, and the white arrowhead indicates the double membrane feature characteristic of
autophagy.
(legend continued on next page)
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the eiF2a pathway (ATF4, CHOP) (Clarke et al., 2014) in MOLM-
14 and primary AML cells (Figures 5B and S5B). GSK621 treat-
ment also induced PERK phosphorylation, amarker of ER stress,
in AML cells (Figure S5C). By contrast, GSK621 did not induce
eIF2a phosphorylation in normal CD34+ hematopoietic progeni-
tor cells (Figure S5D) or in MEFs lacking AMPKa1 and AMPKa2
expression (Figure S5E) (Laderoute et al., 2006), supporting the
notion that eIF2a was a consequence of GSK621-induced
AMPK activation in AML cells.
We followed mRNA expression of the main effectors of the
eIF2a pathway—ATF4, ATG12, and CHOP—in MOLM-14 cells.
We observed that while GSK621 enhanced their expression
compared to vehicle-treated cells, ATF4, ATG12, and CHOP
mRNA remained at steady-state in AML cells co-treated with ra-
pamycin and GSK621 (Figure 5C). In fact, the level of ATF4 pro-
tein increased with mTORC1 activity induced by TSC2 ablation
and decreased with mTORC1 inhibition by rapamycin treatment
in MOLM-14 cells (Figure 5D). These results suggest that
mTORC1 is required for the full activation of eIF2a pathway
upon GSK621 treatment.
To further understand the contribution of the eIF2a pathway to
GSK621-induced cytotoxicity, we first ectopically expressed an
inactive EIF2A S52A mutant (Harding et al., 2009) in MOLM-14
cells. Cells expressing EIF2A S52A had reduced GSK621-
induced ATF4 expression and were partially protected from
GSK621-induced cytotoxicity (Figure S5F). We inhibited the
UPR pathway with phenylbutyric acid (PBA) (Ozcan et al.,
2006) or a PERK inhibitor (GSK2656157 compound (Atkins
et al., 2013) in MOLM-14 cells and observed that co-incubation
with these compounds significantly protected from GSK621-
induced cytotoxicity (Figures S5G and S5H). Next, we used
pharmacological and genetic approaches to overactivate eIF2a
signaling pathway in MOLM-14 cells. Thapsigargin is an ER cal-
cium ATPase inhibitor that activates the eIF2a/ATF4 pathway
(van Galen et al., 2014). In MOLM-14 cells, co-incubation with
thapsigargin or ectopic overexpression of ATF4 abrogated the
protective effect of rapamycin on GSK621-induced cytotoxicity
(Figures 5E and 5F). These data indicate that the eIF2a/ATF4
pathway is involved in the synthetic lethality between AMPK
and mTORC1 co-activation in AML.
DISCUSSION
AMPK is a central regulator of energy balance in mammalian
cells. Several groups have previously demonstrated its impor-(B) Western blotting of MOLM-14, HL-60, OCI-AML3 AML cell lines and primary A
rapamycin using anti-LC3B antibody.
(C and D) Flow cytometry analysis of monodansylcadaverin (MDC) staining of veh
and D: fluorescence intensity quantification, n = 6).
(E) Immunofluorescence analysis using an anti-LC3B antibody (left) and quantifica
MOLM-14 cells.
(F) MOLM-14 cells were cultured 48 hr with vehicle, 30 mM GSK621, 10 mM chlor
annexin V staining experiments (n = 5).
(G) ATG7 knockdownwas induced inMOLM-14 cells, whichwere then treatedwith
V binding (n = 3). Top: western blotting with ATG7 and LC3B antibodies.
(H) Colony formation in MOLM-14 cells lentivirally transduced with scramble or A
then cultured in methylcellulose for 7 days. b-actin is used as a control for loading
***p > 0.001, ****p < 0.0001.
1452 Cell Reports 11, 1446–1457, June 9, 2015 ª2015 The Authorstance in normal hematopoietic stem cell homeostasis (Gan
et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010).
Here, we showed that specific pharmacological AMPK activa-
tion suppresses tumor growth in AML. GSK621 exerted signifi-
cant anti-leukemic activity against AML cell lines in vitro and
in vivo, as well as primary human AML samples. Strikingly,
GSK621 targets leukemic progenitor cells but spares normal hu-
man hematopoietic progenitor cells, highlighting the importance
of AMPK in transformed cells and suggesting a promising thera-
peutic opportunity for AMPK activation in AML.
Among mechanisms underlying cytotoxicity downstream of
GSK621 treatment, we observed both apoptosis and autophagy.
Autophagy is generally enhanced by AMPK activation in parallel
with other energy-sparing processes (Egan et al., 2011; Kim
et al., 2011; Sheen et al., 2011) and has been implicated in
chemotherapy resistance (Sui et al., 2013) and cell survival after
oncogenic stress (Elgendy et al., 2011). In contrast, we found
that GSK621 treatment led to autophagic cell death in AML.
mTORC1 is the essential negative regulator of nutrient starva-
tion-induced autophagy (Levine and Kroemer, 2008) and
AMPK inhibition contributes to autophagy-mediated cell survival
in this context (Kim et al., 2011). In AML, we found that specific
mTORC1 inhibition did not promote autophagy, in contrast to
most currently described models (Kim et al., 2011). We also
observed a dissociation between AMPK activation andmTORC1
inhibition, as recently reported in glioma cells (Liu et al., 2014). As
such, GSK621 induces mTORC1-independent autophagy
downstream of AMPK.
To date, no evidence of oncogenic addiction to mTORC1 has
been observed in AML, despite the finding of constitutive
mTORC1 activity in this disease (Tamburini et al., 2009).
Furthermore, despite the prevailing view of mTORC1 as a target
for pharmacological inhibition in cancer (Kelsey and Manning,
2013), clinical trials of mTORC1 inhibitors such as rapamycin
have failed to demonstrate broad activity in AML (Amadori
et al., 2012; Perl et al., 2009). Here, we propose amodel in which
mTORC1 and AMPK contribute to a unique, synthetic lethal
interaction in AML. Sustained mTORC1 activation in AML was
required for cytotoxicity induced by activated AMPK. This cyto-
toxicity could be abrogated pharmacologically by rapamycin or
amplified by mTORC1 overactivation driven by TSC2 loss. In
normal hematopoietic progenitors, low mTORC1 activity and/
or coupled AMPK and mTORC1 activities (Figure S5D)—which
is in contrast to the observations made in AML—can explain
the limited toxicity of GSK621 treatment. Indeed, syntheticML samples (AML#1 and AML#14) treated 24 hr with 30 mMGSK621 or 10 nM
icle- or GSK621 (30 mM)-treated MOLM-14 cells (C: representative histograms
tion of LC3B dots signal intensity (right) in vehicle- or GSK621-treated (30 mM)
oquine, or combination. Top: western blotting using LC3-B antibody; bottom:
vehicle or 30 mMGSK621 for 48 hr. Bottom: flow cytometry analysis of annexin
TG7 shRNA. Cells were incubated for 48 hr with vehicle or 30 mM GSK621 and
. Results in the graphs are expressed as the mean ± SEM. *p < 0.05, **p < 0.01,
Figure 4. AMPK and mTORC1 Co-activation Is Synthetically Lethal in AML
(A) Schematic representation of the oncogene addiction (1) and synthetic lethal (2) hypothesis concerning the role of mTORC1 upon AMPK activation.
(B) Western blotting in MOLM-14 cells treated during 2 or 4 hr with 30 mMGSK621 (left) or in HL-60 and OCI-AML3 cell lines and primary sample AML#3 treated
6 hr with vehicle, 10 nM rapamycin, or 30 mM GSK621 (right) using anti-phospho-ACC (S79), -phospho-p70S6K (T389), -ACC, and -P70S6K antibodies.
(C) Right: western blotting of humanCD34+ hematopoietic progenitors (referred to as ‘‘CD34+ cells’’) lentivirally transducedwith empty vector or with a HA-tagged
myrAKT construct. Left: flow cytometry determination of Annexin V binding in CD34+ cells lentivirally transduced with empty vector or with a myrAKT construct
and treated with vehicle or 10 nM rapamycin for 24 hr followed by addition of either vehicle or 100 mM GSK621 for 48 hr (n = 3).
(legend continued on next page)
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lethality observed with AMPK activation can be induced solely
by myr-AKT-driven mTORC1 activation in these cells. The
magnitude of mTORC1 activity thus determines the impact of
AMPK activation and therefore the specific cytotoxicity of
GSK621.
From an unbiased analysis, we found that co-activation of
the eIF2a/ATF4 pathway by both mTORC1 and AMPK was
associated with the selective cytotoxicity of GSK621 on AML
cells versus normal hematopoietic cells. In fact, Ozcan and
colleagues previously showed that mTORC1 overactivation
resulting from tuberous sclerosis complex (TSC1 or TSC2)
disruption triggers the unfold protein response, which includes
eIF2a activation (Ozcan et al., 2008). Recent work showed that
transcriptional regulation of ATF4 by mTORC1 involves the
trans-activating function of c-MYC (Babcock et al., 2013). In
AML, we showed that mTORC1 activation promoted ATF4
accumulation and that overexpression of ATF4 abrogated
protection from GSK621 cytotoxicity induced by rapamycin
in leukemic cells. Together these results suggest that the
eIF2a/ATF4 signaling pathway coordinate signals resulting
from AMPK and mTORC1 co-activation leading to AML cell
death.
These data demonstrate an unexpected role ofmTORC1 in the
cytotoxic response to metabolic stress and provide the biologic
rationale for testing AMPK activators in clinical trials in AML and
other cancers with constitutive mTORC1 signaling.
EXPERIMENTAL PROCEDURES
Full details are provided in the Supplemental Experimental Procedures.
Human Primary Samples
Patients and healthy donors provided a written informed consent in accor-
dance with the declaration of Helsinki. The characteristics of AML patients
are provided in Table 1.
Cell Lines
Characteristics of cell lines used are provided in Table S1.
Reagents and Constructs
Rapamycin, chloroquine, oligomycin, puromycin, monodansylcadaverin (MDC),
thapsigargin, and doxycycline (Dox) were from Sigma-Aldrich (Sigma-Aldrich).
A769662 was form Santa Cruz Biotechnology. The 991 compound was synthe-
sized by GlaxoSmithKline Research Center, as reported (Xiao et al., 2013). We
utilized myrAKT and ATF4 plasmids from Addgene (number 31790 and 26114,
respectively) (Calvisi et al., 2011; Wang et al., 2009) that were cloned using
the Gateway system (Life Technologies) in pLenti PGK Blasti DEST or in pLenti
PGK Puro DEST (Addgene plasmids 19068 and 17451, respectively) (Campeau
et al., 2009).(D) Left: annexin V binding inMOLM-14 cells lentivirally transducedwith nontarget
Right: western blotting of CTR or TSC2 sgRNA-expressing MOLM-14 cells.
(E) Annexin V binding in MOLM-14 cells transduced with doxycycline-inducible m
then vehicle or 30 mM GSK621 was added (n = 3).
(F) Annexin V binding in AML cell lines treated with vehicle or 10 nM rapamycin f
(G) Primary AML samples were treated with vehicle or 10 nM rapamycin for 24 hr,
later by annexin V binding (n = 7).
(H) Annexin V binding in AML cell lines treated with vehicle or 10 nM rapamycin fo
(n = 3).
(I) May-Gru¨nwald Giemsa (MGG) coloration of cytospin from a primary AML sam
30 mM GSK621. b-actin is used as a control for loading. Results in the graphs ar
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PLKO and Tet-pLKO-puro plasmids (Addgene plasmids 8453 and 21915,
respectively (Stewart et al., 2003; Wiederschain et al., 2009)) and pTRIPZ
plasmid (Thermo Scientific) were used to generate lentivirus able to stably
deliver constitutive or doxycycline-inducible hairpins to AML cell lines.
CRISPR/Cas9 Genome Editing
We cloned small guide RNA (sgRNA) guides targeting by using the Optimized
Crispr Design application from Dr. F. Zhang’s lab (http://crispr.mit.edu/) into
the lentiCRISPR plasmid (Addgene plasmid 49535).
Monodansylcadaverine
Cells were incubated 0.5 hr at 37C with 5 mMmonodansylcadaverin and then
washed three times and analyzed on a LSRII cytometer (excitation and emis-
sion wavelength 353 and 512 nm, respectively).
AML Xenografts in NUDE Mice
All experiments were conducted in accordance with the guidelines of the As-
sociation for Assessment and Accreditation of Laboratory Animal Care Inter-
national and after approval of the local ethics committee.
Mice Leukemic Cells Clonogenic Assay
Colony formation was assayed in bone marrow cells from C57B6 mice trans-
duced with MLL-ENL or FLT3-ITD oncogenes. After 1 week of culture with
10 ng/ml interleukin 6 (IL-6) and 50 ng/ml SCF (Peprotech), 5 3 104 cells
were plated in Methocult medium with vehicle or 30 mmol/l GSK621. Colonies
were numbered at 7 days.
Transmission Electron Microscopy
AML cells (106) were fixed and then dehydrated by successive ethanol washes
(70%, 90%, 100%, and 100%) and impregnated with epoxy resin. Sections
(80–90 nm) were prepared using a Reichert Ultracut S ultramicrotome, stained
with 2% uranyl acetate plus Reynold’s lead citrate, and visualized under a
JEOL 1011 transmission electron microscope with a GATAN Erlangshen
charge-coupled device (CCD) camera.
Immunofluorescence
MOLM-14 cells (2 3 105) were fixed in methanol after cytocentrifugation,
washed in PBS, and blocked in 3% BSA PBS. Cells were incubated 1 hr
with anti-LC3 antibody and then with GFP-coupled anti-rabbit antibody.
Analysis was done on a Zeiss inverted microscope, and spots were auto-
matically quantified with the open-source software CellProfiler (Kamentsky
et al., 2011) with the Enhance Features and Identify Primary Objects
modules.
qPCR
qPCR was then performed on a Lightcycler 480 (Roche). Primers sequences
are provided in the Supplemental Experimental Procedures.
Gene Expression Profiling
cDNA were hybridized on GeneChip Human Gene MoGene-2_0-st from Affy-
metrix GeneChips. To find differentially expressed genes, we applied a clas-
sical ANOVA for each gene andmade pairwise Tukey’s post hoc tests between(CTR) or TSC2 sgRNA and treatedwith a dose range of GSK621 for 48 hr (n = 3).
TOR or raptor shRNA treated with 200 ng/ml doxycycline (Dox) for 4 days and
or 24 hr and then vehicle or 30 mM GSK621 for 48 hr (n = 4).
and then vehicle or 30 mMGSK621 was added. Apoptosis was measured 48 hr
r 24 hr and then vehicle or 100 mM 991 and vehicle or 200 mMA769662 for 48 hr
ple AML#6 treated with vehicle, 30 mM GSK621, or with 10 nM rapamycin and
e expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p > 0.001.
Figure 5. Synthetic Lethality between AMPK and mTORC1 Involves eIF2a/ATF4
(A) Heatmap representing the gene expression variations of 13 genes involved in the unfold protein response pathway. MOLM-14 cells were treated 24 hr with
vehicle or 10 nM rapamycin and then exposed 12 hr to 30 mM GSK621.
(B) Western blotting in a primary AML sample (AML#3) and in the MOLM-14 cell line treated with vehicle or 30 mM GSK621 for 24 hr using anti-phospho-eIF2a
(S51), anti-eIF2a, -ATF4, and -CHOP antibodies.
(C) Quantification by qPCR of ATF4, ATG12, and CHOP mRNA (normalized to GAPDH and UBC) in MOLM-14 cells treated with vehicle or 10 nM rapamycin for
24 hr and then vehicle or 30 mM GSK621 for 24 hr (n = 3).
(D) MOLM-14 cells were lentivirally transduced with a control (CTR) or a TSC2 CRISPR guide. Both CTR and TSC2 cell lines were treated with vehicle or 10 nM
rapamycin during 24 hr and then incubated 6 hr with vehicle or 30 mM GSK621. Anti-phospho-P70S6K (T389), anti-P70S6K, anti-TSC2, anti-ATF4, anti-peIF2a
(S51), and anti-eIF2a antibodies were used for western blotting.
(legend continued on next page)
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groups. Then, we used p values and fold changes to filter and select differen-
tially expressed genes with the Ingenuity Pathway Analysis software.
Statistics
Differences between the mean values obtained for the experimental groups
were analyzed using the two-tailed Student’s t test. Statistical analyses were
performed using Prism software (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.04.063.
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